Get the latest crypto news, updates, and reports by subscribing to our free newsletter.
Giấy phép số 4978/GP-TTĐT do Sở Thông tin và Truyền thông Hà Nội cấp ngày 14 tháng 10 năm 2019 / Giấy phép SĐ, BS GP ICP số 2107/GP-TTĐT do Sở TTTT Hà Nội cấp ngày 13/7/2022.
© 2026 Index.vn
MB Securities Joint Stock Company (MBS) reported its Q1 2026 financial results, becoming one of the first brokerage firms to reveal the three-month performance. Specifically, MBS recorded operating revenue of VND 1,019 billion, up 52% year over year. In the proprietary trading segment, profit from financial assets measured at fair…
Curanex Pharmaceuticals, Inc. (Nasdaq: CURX) said on April 8, 2026 that management has highlighted five additional patient cases it believes further support the potential of its lead candidate in cancer cachexia, advanced cancer supportive care and other serious disease settings marked by profound physical decline, inflammation, metabolic dysfunction and loss of functional capacity.
The company said the new cases follow a previously disclosed patient account involving “Johnny,” which management described as an initial clinically relevant signal related to cancer cachexia and supportive oncology. Curanex said the combined set of patient experiences may indicate broader relevance for helping patients maintain or recover appetite, strength, physical condition, mobility and quality of life.
The patient was receiving care at Memorial Sloan Kettering Cancer Center (MSKCC) for advanced thymic carcinoma with pulmonary embolism, pulmonary hemorrhage and bilateral lung and pleural metastases. Curanex reported that the pleural tumor measured 9.9 × 3.3 cm and was visibly vascularized. The patient’s wife said doctors warned that severe left abdominal pain could cause fainting and that estimated survival was approximately one month.
According to the patient account, after taking the company’s product for about 20 days, pain disappeared, night sweats resolved, hemoptysis stopped, analgesic injections were no longer needed, and appetite and sleep improved. The company also reported a visible reduction of the pleural tumor. The patient account described projected survival extending from weeks to more than one year, with improved quality of life.
The patient was evaluated in Flushing, New York and later referred to MSKCC for metastatic small cell lung cancer. Curanex reported visible tumors in the neck, chest and abdomen, with the largest neck tumor measuring approximately 1 × 1 cm. The patient’s oncologist told her family to prepare for her passing, saying she had only weeks to live, and the patient had exhausted chemotherapy, radiotherapy, immunotherapy and investigational therapies.
Before taking the company’s product, the patient account described profound cachexia, severe weakness and being barely able to eat. Curanex said that within about one month she gained about 17 pounds (approximately 7.7 kg), her voice returned from weak to strong, and she resumed normal eating and physical activity. After about two months, the patient account described walking briskly and jogging lightly, and the previously visible neck tumor was no longer detectable. The company reported projected survival extending from weeks to more than three years.
Curanex said an 80-year-old male patient developed multi-organ failure following pancreatic cancer resection and was hospitalized at NewYork-Presbyterian Hospital in Lower Manhattan. The hospital notified the family of a critical condition with expected survival of only days or hours. The patient account described inability to eat, severe edema in the feet and legs, severe hypotension, being bedridden and requiring nasogastric tube feeding.
According to the patient account, the morning after taking the company’s product, he was able to eat small amounts that evening. Within a week, he could eat normally, and his blood pressure and liver and kidney function returned to normal. Curanex reported that within two weeks he regained enough strength to be discharged home. After returning home, the patient account described daily wheelchair outings for exercise and fresh air, with continued improvement in mental state. The company said the patient account described projected survival extending from hours to more than one year with substantial improvement in condition and quality of life.
Curanex reported that Chris, an 82-year-old male patient under long-term care at MSKCC, developed end-stage liver cirrhosis with massive ascites, with his abdomen swelling to the size of a full-term pregnancy. The patient account described extreme weakness, inability to get out of bed independently, inability to walk, barely able to eat, and inability to urinate spontaneously for over a year, relying on daily drainage of ascitic fluid. After being told there were no further treatment options, he entered hospice care with an estimated life expectancy of one to two months.
According to the patient account, on the fourth day after taking the company’s product, he urinated in large quantities and his appetite returned. By day eleven, the drainage tube stopped producing fluid. Curanex said that after one month he used a walker and rode a stationary bicycle to exercise his legs and was eating regularly. After two months, the patient account described walking freely and cooking in the kitchen, with the abdomen returning to normal. After three months, the patient account described walking normally and having energy to do so. The company reported that the patient subsequently survived for more than one year with improved mobility and quality of life.
The patient, Curanex said, had end-stage renal disease and received thrice-weekly hemodialysis at North Flushing Dialysis Center. The patient account described severe weakness, walking slowly with a cane, severe bilateral leg pain, severe pleural effusion, hydronephrosis and complete loss of spontaneous urination.
According to the patient account, spontaneous urination returned within about one week of taking the company’s product. Curanex said follow-up imaging confirmed complete resolution of pleural effusion and hydronephrosis, bilateral leg pain fully resolved, and physical strength recovered significantly. The company reported continued improvement in mental state and overall condition, including walking more than 10,000 steps per day independently without any assistive device.
Curanex said that across the five cases—spanning different disease backgrounds—management observed consistent themes including severe weakness, loss of appetite, impaired mobility, profound physical deterioration, metabolic instability and loss of independent function. The company said that in several cases, improvements in physical condition helped patients regain the ability to eat, walk, sleep and live more normally, and that these observations are relevant to cancer cachexia and supportive oncology.
Jun Liu, Chief Executive Officer of Curanex, said: “What stands out to us is not simply the severity of these cases, but that across very different disease settings, we are repeatedly hearing from patients about the return of appetite, the rebuilding of strength, the ability to walk again, and the return to ordinary daily life. We believe this growing body of patient experience may support the possibility that our lead candidate has broader relevance in one of the most difficult areas of medicine: helping seriously ill patients maintain or rebuild the physical resilience they need to endure disease. If future research supports these observations, we believe the implications for cancer cachexia, supportive oncology, and other serious diseases involving systemic decline could be medically important and commercially significant.”
Curanex said it has expanded its strategic development focus to include cancer cachexia, which management described as one of the largest unmet needs in supportive oncology. The company said it believes the market opportunity is supported by the seriousness of the condition, the absence of approved therapies in the United States specifically for cancer cachexia, and the potential value of a candidate capable of helping patients maintain body weight, appetite, strength, mobility or the ability to continue receiving care. Curanex also said the patient observations align with its broader interest in diseases involving inflammation, metabolic disruption and physical decline.
Curanex cautioned that the reports reflect only individual patient accounts, are observational in nature, and do not establish safety or efficacy or predict similar outcomes in other patients. The company said it believes the consistency of certain observations across multiple severe cases may help inform future development priorities in cancer cachexia, advanced cancer supportive care and other serious disease settings.
Curanex Pharmaceuticals Inc. is a pharmaceutical development company headquartered in Jericho, New York. The company said its lead asset, Phyto-N, is being developed for ulcerative colitis and is being advanced through preclinical and IND-enabling activities in support of a planned IND submission in the fourth quarter of 2026. Curanex also said it is evaluating broader pipeline opportunities intended to expand its long-term therapeutic platform.
The company stated that all statements other than historical facts are forward-looking statements, made as of the date of the announcement, and involve risks and uncertainties. Curanex said investors should read its “Risk Factors” section in its Annual Report on Form 10-K dated March 30, 2026 and risk factors in other SEC filings.
Contact: Curanex Pharmaceuticals Inc. Tel: (212) 671-1020 / (718) 673-6078. Email: ir@curanexpharma.com
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
